NCT05558709Recruiting
Social-cognitive Functioning: Validation of a New Neuropsychological Test
Social-cognitive Functioning: Validation of a New Neuropsychological Test and Prediction of Social Behavioural Disorders in Daily Life
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders. Their assessment is therefore essential, particularly in order to propose early and adapted care. However, this assessment remains limited today. A new serious game-type test, REALSoCog, has been developed to address the shortcomings of current tools and to highlight disturbances in social behaviors. The latter are not always observed in consultation although they are often reported by caregivers. The objective of this research is therefore to validate the REALSoCog task in a pathological population (currently being standardized in the general population: CER-U, IRB N°: 00012020-115). The clinical interest of this task will be tested with a group of patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL), fronto-temporal lobar degeneration (FTD)) in order to assess its sensitivity and specificity in the detection of social-cognitive disturbances, and in particular in terms of social behaviors (detection of social behavioral disorders reported in daily life). The objective is also to document the socio-cognitive profiles in the mentioned diseases thanks to a more ecological test, and to better understand the links between socio-cognitive processes on the one hand, and individual characteristics on the other hand (e.g. mood and social participation).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 20 Sept 2022
- Start date
- 4 Feb 2026
- Primary completion date
- 4 Feb 2029
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT05558709
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 4 Feb 2026 to the primary completion date, 4 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neurological or psychiatric comorbidity
Age
- Notable sensory disorders (e.g., profound or total deafness, age-related macular degeneration, blindness, etc.) that may interfere with experimental completion.
Other
- For patients:
- Opposition to participation in the study
Who the study is looking for
- For patients:
- Patient aged between 18 and 90 years
- Mini Mental State Examination (MMSE) score greater than or equal to 20
- Patient able to express his or her non-opposition to participate in the study in an informed and autonomous manner
- Patient with a neurodegenerative pathology: FTD, AD or LBD.
- For caregivers:
- Over 18 years of age
- Regular contact with the patient (≥ 2 times per month)
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital de la Pitié-Salpêtrière Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.